China (Mainland)
Diamondsupplier 
High quality in stock CAS NO.936091-26-8 CAS NO.936091-26-8
- FOB Price: USD: 1.00-3.00 /Kilogram Get Latest Price
- Min.Order: 1 Kilogram
- Payment Terms: T/T,Other
- Available Specifications:
10KG(1-20)Kilogram10KG(20-30)Kilogram10g(1-20)Kilogram
- Product Details
Keywords
- 936091-26-8
- 936091-26-8 TG 101348SAR302503
- TG 101348SAR302503
Quick Details
- ProName: High quality in stock CAS NO.936091-2...
- CasNo: 936091-26-8
- Molecular Formula: C27H36N6O3S
- Appearance: crystal, powder
- Application: Pharmaceutical intermediates
- DeliveryTime: 1-2 days
- PackAge: as your request
- Port: Qingdao port
- ProductionCapacity: 10 Kilogram/Day
- Purity: 99%
- Storage: stay in dry, cool and well-sealed
- Transportation: EMS,HK EMS,FEDEX,DHL,TNT
- LimitNum: 1 Kilogram
- Moisture Content: 0.01%
- Impurity: 0.001%
- Loss On Drying: 0.2%
- Melting Point: 177℃ ~ 181℃
- Specific Rotation: +27°
- Assay: 99.2%
Superiority
Details
TG101348 (SAR302503) is an orally available inhibitor of Janus kinase 2 (JAK-2) developed for the treatment of patients with myeloproliferative diseases including myelofibrosis. TG101348 acts as a competitive inhibitor of protein kinase JAK-2 with IC50=6 nM; related kinases FLT3 and RET are also sensitive, with IC50=25 nM and IC50=17 nM, respectively. Significantly less activity was observed against other tyrosine kinases including JAK3 (IC50=169 nM).[1] In treated cells the inhibitor blocks downstream cellular signalling (JAK-STAT) leading to suppression of proliferation and induction of apoptosis.
Myelofibrosis is a myeloid malignancy associated with anemia, splenomegaly, and constitutional symptoms. Patients with myelofibrosis frequently harbor JAK-STAT activating mutations that are sensitive to TG101348. Phase I trial results focused on safety and efficacy of TG101348 in patients with high- or intermediate-risk primary or post–polycythemia vera/essential thrombocythemia myelofibrosis have been published in 2011.
Our advangtage: